You can't seriously imagine GSK could BTA by paying $2.35/share do you? Who would agree to that? A takeover premium would price it closer to $12 with all the associated hype around vastly increased demand for Relenza, LANI and other BTA blue sky projects. I also doubt Costello would wear it given adverse publicity surounding the court case and Sankyo would be highly resistant as a JV partner.
- Forums
- ASX - By Stock
- media coverage
You can't seriously imagine GSK could BTA by paying $2.35/share...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online